Pelareorep Gets FDA Orphan Drug Nod for Ovarian Cancer

Article

The US Food and Drug Administration has granted Orphan Drug Designation to pelareorep (Reolysin) for the treatment of ovarian cancer.

Pelareorep (Reolysin) is being tested in patients with ovarian epithelial, primary peritoneal, and fallopian tube carcinoma.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to the oncolytic virus pelareorep (Reolysin) for the treatment of ovarian cancer.

The drug, developed by Oncolytics Biotech Inc, is currently being tested in a phase II trial.

“This is an important regulatory milestone for Oncolytics and will provide us with a number of benefits as we advance the development and commercialization process for Reolysin,” said Dr. Brad Thompson, president and CEO of the company, in a press release. “Ovarian cancer is a devastating disease that represents a significant unmet need, particularly for those patients diagnosed in later stages.”

Patients diagnosed with ovarian cancer at an early, localized stage have a 5-year survival rate of 92%, but about 85% of cases are diagnosed at a more advanced stage of the disease.

The initial phase I/II trial of pelareorep (OSU-07022) studied the drug for safety and tolerability, and to determine an optimal dose for treating patients with ovarian epithelial, primary peritoneal, or fallopian tube carcinoma that failed to respond to platinum-based chemotherapy. The drug was delivered via concurrent intravenous and intraperitoneal administration.

A randomized phase II trial of pelareorep (GOG186H), which completed enrollment in September 2014, is testing weekly paclitaxel with or without pelareorep in patients with persistent or recurrent ovarian, primary peritoneal, or fallopian tube carcinoma. The primary endpoint of the trial is progression-free survival; secondary endpoints are tumor response and overall survival.

The FDA grants Orphan Drug Designation to drugs or biologics with the potential to treat rare diseases-affecting fewer than 200,000 people-in the United States. The program offers incentives for companies to develop agents for these rare diseases.

About 193,203 women are currently living with ovarian cancer in the United States. In 2014, an estimated 21,908 American women were diagnosed with ovarian cancer, , according to the American Cancer Society, and an estimated 14,270 patients died of the disease. Among women, ovarian cancer accounts for roughly 5% of all cancer deaths each year.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer

April 11th 2024
Article

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024
Article

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer

March 24th 2024
Article

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.

FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

March 22nd 2024
Article

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.